Bilateral DLPC tDCS in Drug-resistant Migraine

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

April 30, 2023

Study Completion Date

August 31, 2023

Conditions
Migraine
Interventions
DEVICE

Transcranial direct current stimulation (tDCS)

TDCS was delivered by a DC-Stimulator (Newronika, Italy) over both DLPC. The electrodes (35 cm2) were soaked in 0.9% NaCl. The anode was positioned on the left dorsolateral prefrontal cortex and the cathode on the right dorsolateral prefrontal cortex.

DRUG

anti-CGRP-mAbs

CGRP-mAbs have been the first target-driven treatment to be approved for migraine prevention. Their efficacy and safety have been demonstrated in randomized controlled trials (RCT) as well as, in real-world evidence (RWE) studies

Trial Locations (1)

45600

Clinica de Intervencion en Neurociencias, Talavera de la Reina

All Listed Sponsors
lead

Clínica de Intervención en Neurociencias

OTHER

NCT06079801 - Bilateral DLPC tDCS in Drug-resistant Migraine | Biotech Hunter | Biotech Hunter